Arcadia Biosciences, Inc. Quarterly Debt-to-equity in % from Q1 2016 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Arcadia Biosciences, Inc. quarterly Debt-to-equity history and growth rate from Q1 2016 to Q3 2024.
  • Arcadia Biosciences, Inc. Debt-to-equity for the quarter ending September 30, 2024 was 51.6 %, a 5.39% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 51.6 -2.94 -5.39% Sep 30, 2024
Q2 2024 52.1 +2.31 +4.64% Jun 30, 2024
Q1 2024 52.2 +8.28 +18.8% Mar 31, 2024
Q4 2023 60 +26.8 +80.7% Dec 31, 2023
Q3 2023 54.6 +20.1 +58.5% Sep 30, 2023
Q2 2023 49.8 +11.9 +31.5% Jun 30, 2023
Q1 2023 44 -3.94 -8.23% Mar 31, 2023
Q4 2022 33.2 -20.9 -38.6% Dec 31, 2022
Q3 2022 34.4 -24.8 -41.9% Sep 30, 2022
Q2 2022 37.9 -37.1 -49.5% Jun 30, 2022
Q1 2022 47.9 -46.2 -49.1% Mar 31, 2022
Q4 2021 54.1 -82.5 -60.4% Dec 31, 2021
Q3 2021 59.2 -155 -72.4% Sep 30, 2021
Q2 2021 75 -131 -63.6% Jun 30, 2021
Q1 2021 94 -114 -54.8% Mar 31, 2021
Q4 2020 137 -148 -51.9% Dec 31, 2020
Q3 2020 214 +8.46 +4.11% Sep 30, 2020
Q2 2020 206 +21.8 +11.8% Jun 30, 2020
Q1 2020 208 +5.76 +2.85% Mar 31, 2020
Q4 2019 284 +80.1 +39.3% Dec 31, 2019
Q3 2019 206 -22.1 -9.7% Sep 30, 2019
Q2 2019 184 -40.7 -18.1% Jun 30, 2019
Q1 2019 202 -10.2 -4.78% Mar 31, 2019
Q4 2018 204 +40.2 +24.6% Dec 31, 2018
Q3 2018 228 +60.4 +36% Sep 30, 2018
Q2 2018 225 +60.3 +36.6% Jun 30, 2018
Q1 2018 213 +74.5 +54% Mar 31, 2018
Q4 2017 164 +45.7 +38.7% Dec 31, 2017
Q3 2017 168 +65.7 +64.4% Sep 30, 2017
Q2 2017 165 +72.4 +78.4% Jun 30, 2017
Q1 2017 138 +53.3 +62.9% Mar 31, 2017
Q4 2016 118 Dec 31, 2016
Q3 2016 102 Sep 30, 2016
Q2 2016 92.3 Jun 30, 2016
Q1 2016 84.7 Mar 31, 2016
* An asterisk sign (*) next to the value indicates that the value is likely invalid.